Scientific Congresses

At #ESMO24, we presented longer-term data from a Phase 2 single-arm study of patients with BRAF V600E-mutant metastatic non-small cell #LungCancer. Learn more here: on.pfizer.com/3Bg952Q

Today, we shared new research highlighting findings from 5-year follow-up analyses in people with previously untreated ALK+ advanced NSCLC at #WCLC24. These insights underscore our commitment to improving patient outcomes with breakthrough #LungCancer research.

Follow Pfizer during #WCLC24 as we share our latest advancements in #LungCancer research. Through continued innovation, we’re discovering ways to accelerate breakthroughs to help people with cancer live better and longer lives.

Checking in from Pfizer’s #GlobalIBDCommunitySummit. This summit is more than a meeting. It’s a chance to share diverse, “uninhibited” views on the community’s most urgent needs. Stay tuned for highlights from this important event.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and is aggressive and difficult to treat. Don't miss our oral presentation at #ASCO24 to hear more about how we’re working to address unmet needs for people with relapsed or refractory #DLBCL.

Join us, alongside our partner @AstellasUS, at #ASCO24 to learn more about a health-related quality of life analysis in patients with high-risk biochemically recurrent #ProstateCancer. on.pfizer.com/453HAVl

We are excited to be at #ESMOBreast2024 this week, where we will share data for our investigational next-generation therapies for hormone receptor positive (HR+) metastatic #breastcancer.

For people with metastatic castration-resistant #ProstateCancer (mCRPC), there is a need for early detection and treatment advances. We’re proud to support the #ProstateCancer community at #AUA24, by sharing our latest research and real-world data.

Join us at #AUA24, where we’ll share some of our latest findings in #ProstateCancer research as part of our commitment to outpace, outsmart, and outmaneuver cancer. Together we can #OutdoCancer.

We’re looking forward to #ASCO24 next month, where we’ll highlight our progress in advancing potential standards of care across our key tumor areas and core scientific modalities. Learn more here: on.pfizer.com/49YUGUL

Within 5-7 years of diagnosis, 10-20% of #ProstateCancer patients develop metastatic castration-resistant prostate cancer. Learn more about Pfizer’s research in this disease at #AACR24.

At Pfizer, we are paving the way for breakthrough research and treatment in breast cancer. Join us at #AACR24 to learn more about the discovery & development of our next-generation CDK4 inhibitor.

We enjoyed seeing everyone at the 2023 American College of Rheumatology (ACR) meeting. Thank you, ACR, for an amazing event.

We enjoyed seeing everyone at the 2023 American College of Allergy, Asthma & Immunology (ACAAI) meeting. Thank you, ACAAI, for an amazing event.

Pfizer is committed to making a difference in the lives of patients receiving Ig therapy and is excited to be at the 2023 American College of Rheumatology (ACR) meeting. We look forward to welcoming you at booth #1112.

Pfizer is committed to making a difference in the lives of patients receiving Ig therapy and is excited to be at the 2023 American College of Allergy, Asthma & Immunology (ACAAI) meeting. We look forward to welcoming you at booth #811.

We enjoyed seeing everyone at the 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting. Thank you, AANEM, for an amazing event.

Pfizer is committed to making a difference in the lives of patients receiving Ig therapy and is excited to be at the 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting. We look forward to welcoming you at booth #519.

We're counting down the days until the 2023 American College of Rheumatology (ACR) meeting! Join us to show your support for the Ig community.

We're counting down the days until the 2023 American College of Allergy, Asthma & Immunology (ACAAI) meeting! Join us to show your support for the Ig community.